Cirrhosis and Portal Hypertension: Management of Ascites, Variceal Bleeding, Hepatic Encephalopathy, and HCC Screening

Cirrhosis represents the irreversible end-stage of chronic liver disease characterized by extensive hepatic fibrosis, architectural distortion, and formation of regenerative nodules. This structural remodeling leads to portal hypertension, defined as a hepatic venous pressure gradient (HVPG) ≥10 mmHg, which underlies the major complications of decompensated cirrhosis.

[KEY_CONCEPT] The transition from compensated to decompensated cirrhosis marks a critical prognostic milestone, with median survival dropping from >12 years to 1.8 years.

Pathophysiology of Portal Hypertension

Portal hypertension results from:

• Structural changes: Fibrosis and architectural distortion increase intrahepatic resistance
• Functional alterations: Hepatic stellate cell activation and endothelial dysfunction reduce nitric oxide availability
• Hyperdynamic circulation: Splanchnic vasodilation increases portal blood flow
• Portosystemic collaterals: Development of varices as decompression mechanism

Epidemiology

Cirrhosis affects approximately 1.5 million Americans, with the leading etiologies being:

1. Non-alcoholic steatohepatitis (NASH) - fastest growing indication for liver transplantation
2. Alcohol-related liver disease - accounts for 40-50% of cirrhosis deaths
3. Chronic hepatitis C - declining due to effective direct-acting antivirals
4. Chronic hepatitis B - prevalent globally, controllable with nucleos(t)ide analogs

[CLINICAL_PEARL] The Child-Turcotte-Pugh (CTP) and Model for End-Stage Liver Disease (MELD) scores are essential prognostic tools, with MELD-Na being preferred for transplant allocation.

Decompensated cirrhosis presents with four cardinal complications: ascites, variceal hemorrhage, hepatic encephalopathy, and jaundice. Each represents a distinct pathophysiologic process requiring targeted management.

Ascites

Ascites affects 85% of patients with decompensated cirrhosis and represents the most common complication. The pathogenesis involves:

• Arterial vasodilation hypothesis: Splanchnic vasodilation → effective arterial blood volume depletion → activation of renin-angiotensin-aldosterone system
• Peripheral arterial vasodilation: Primarily mediated by nitric oxide and other vasodilators
• Sodium retention: Enhanced renal sodium reabsorption despite total body sodium excess

[HIGH_YIELD] Ascites development indicates a 50% 2-year mortality rate and should prompt liver transplant evaluation.

Variceal Hemorrhage

Gastroesophageal varices develop when HVPG exceeds 10 mmHg, with bleeding risk when HVPG >12 mmHg. Risk factors include:

• Large varices (>5mm diameter)
• Red wale signs on endoscopy
• CTP class B/C cirrhosis
• Continued alcohol use

[CLINICAL_PEARL] Acute variceal bleeding carries 15-20% mortality at 6 weeks despite modern therapy.

Hepatic Encephalopathy (HE)

Hepatic encephalopathy affects 30-45% of cirrhotic patients, caused by:

• Ammonia accumulation: Impaired hepatic detoxification and portosystemic shunting
• Neuroinflammation: Systemic inflammation affecting blood-brain barrier
• Altered neurotransmission: GABA-ergic tone enhancement

West Haven Criteria for HE Grading:

Hepatocellular Carcinoma (HCC) Risk

Annual HCC incidence ranges from 1-8% depending on etiology:

• Hepatitis B: 0.5-1% (non-cirrhotic), 2-5% (cirrhotic)
• Hepatitis C with cirrhosis: 2-4%
• NASH cirrhosis: 1-3%
• Alcoholic cirrhosis: 1-2%

[HIGH_YIELD] HCC is the third leading cause of cancer-related death worldwide and the fastest-rising cancer-related cause of death in the United States.

Comprehensive evaluation of cirrhotic patients requires systematic assessment of liver function, portal hypertension severity, and complication screening.

Ascites Evaluation

Diagnostic Paracentesis Checklist:

✓ Cell count and differential (PMN >250/μL suggests SBP) ✓ Albumin level (for SAAG calculation) ✓ Total protein (<2.5 g/dL suggests portal hypertension) ✓ Culture (blood culture bottles increase yield) ✓ Gram stain (low sensitivity but high specificity) ✓ Cytology (if malignant ascites suspected)

[KEY_CONCEPT] Serum-Ascites Albumin Gradient (SAAG) is the most accurate test for determining ascites etiology:

• SAAG ≥1.1 g/dL: Portal hypertension (97% accuracy)
• SAAG <1.1 g/dL: Non-portal hypertensive causes

Variceal Screening Algorithm

Newly diagnosed cirrhosis | v EGD within 1 year | ----------- | | No varices Varices present | | Repeat EGD Size assessment in 3 years | ----------- | | Small Large (<5mm) (≥5mm) | | Repeat EGD Start NSBB in 2 years + Band ligation if high-risk

[CLINICAL_PEARL] Non-selective beta-blockers (propranolol, nadolol) reduce portal pressure and are first-line therapy for primary prophylaxis in large varices.

Hepatic Encephalopathy Assessment

Precipitating Factors to Evaluate:

• Infections: Spontaneous bacterial peritonitis, pneumonia, UTI
• GI bleeding: Protein load from blood
• Medications: Sedatives, narcotics, diuretics
• Metabolic: Hyponatremia, hypokalemia, alkalosis
• Constipation: Increased ammonia absorption
• Dehydration: Azotemia

Diagnostic Tests:

• Venous ammonia: Correlates poorly with HE severity but useful for monitoring
• Psychometric tests: Number connection test, digital symbol test
• Critical flicker frequency: Objective measure of minimal HE

HCC Screening Protocol

Barcelona Clinic Liver Cancer (BCLC) Surveillance Recommendations:

[HIGH_YIELD] LI-RADS (Liver Imaging Reporting and Data System) standardizes HCC diagnosis:

• LR-5: Definite HCC (≥95% probability)
• LR-4: Probably HCC (75-94% probability)
• LR-3: Intermediate probability (50-74%)

HCC Diagnostic Criteria:

✓ Lesion >1cm on dynamic imaging ✓ Arterial hyperenhancement in arterial phase ✓ Washout in portal venous or delayed phase ✓ Capsule appearance (supportive feature)

Management of decompensated cirrhosis requires a multidisciplinary approach addressing each complication while optimizing candidacy for liver transplantation.

Ascites Management Algorithm

New-onset ascites | v Diagnostic paracentesis | v First-line therapy: • Spironolactone 100mg daily • Furosemide 40mg daily (2.5:1 ratio) • Sodium restriction <2g/day | v Inadequate response after 1 week? | -------- | | Yes No | | Increase Continue doses therapy (max: Spiro 400mg, Furosemide 160mg) | v Refractory ascites? | v • Large volume paracentesis • TIPS consideration • Liver transplant evaluation

[KEY_CONCEPT] Refractory ascites is defined as ascites that cannot be mobilized or recurs rapidly despite maximum tolerated diuretic therapy.

Large Volume Paracentesis Protocol:

• Volume: Remove >5L constitutes large volume
• Albumin replacement: 8g per liter removed if >5L
• Monitoring: Electrolytes, creatinine within 24-48 hours
• Complications: Post-paracentesis circulatory dysfunction in 15-20%

Variceal Bleeding Management

Acute Management Protocol:

1. Resuscitation: Target Hgb 7-9 g/dL (restrictive strategy)
2. Vasoactive agents: Octreotide 50μg bolus, then 50μg/hr × 5 days
3. Antibiotics: Ceftriaxone 1g daily × 7 days (reduces mortality)
4. Endoscopic therapy: Band ligation preferred over sclerotherapy
5. TIPS: If rebleeding within 5 days (early TIPS)

[CLINICAL_PEARL] Antibiotic prophylaxis reduces infection rates from 25% to 10% and decreases mortality in acute variceal bleeding.

Secondary Prophylaxis Options:

Hepatic Encephalopathy Treatment

First-Line Therapy:

• Lactulose: 30-45 mL BID, titrate to 2-3 soft stools daily
• Rifaximin: 550 mg BID (reduces HE episodes by 58%)
• Combination therapy: Superior to lactulose alone

Acute HE Management:

1. Identify precipitants: Treat underlying causes
2. Lactulose: 30 mL q1-2h until bowel movement, then q6-8h
3. Rifaximin: Add if recurrent episodes
4. Avoid: Protein restriction (worsens malnutrition)
5. Consider: L-ornithine L-aspartate in refractory cases

[HIGH_YIELD] Protein restriction is contraindicated in HE as it worsens muscle wasting without improving outcomes.

Liver Transplant Evaluation

Indication Criteria:

✓ MELD-Na ≥15 with complications ✓ Refractory ascites despite optimal medical therapy ✓ Recurrent variceal bleeding on prophylaxis ✓ Persistent HE grade ≥2 ✓ HCC within Milan criteria ✓ Hepatopulmonary syndrome ✓ Portopulmonary hypertension

Absolute Contraindications:

• Active substance abuse
• Uncontrolled psychiatric illness
• Severe cardiopulmonary disease
• Active extrahepatic malignancy
• Severe, irreversible neurologic disorder

[CLINICAL_PEARL] Early transplant referral (MELD 15-20) allows time for evaluation and optimization before critical illness develops.

Understanding the natural history and prognostic implications of cirrhotic complications is essential for timing interventions and counseling patients.

Spontaneous Bacterial Peritonitis (SBP)

SBP occurs in 15-25% of hospitalized patients with ascites and carries significant mortality risk.

Diagnostic Criteria:

✓ Ascitic fluid PMN >250 cells/μL ✓ Positive culture (60% of cases) ✓ Absence of surgical source of infection

Management Protocol:

• Empiric antibiotics: Ceftriaxone 2g IV daily or cefotaxime 2g IV q8h
• Albumin therapy: 1.5g/kg on day 1, 1g/kg on day 3 (reduces mortality)
• Treatment duration: 5-7 days minimum
• Follow-up paracentesis: If clinical deterioration

[HIGH_YIELD] Albumin administration in SBP reduces mortality from 29% to 10% by preventing renal dysfunction.

Secondary Prophylaxis Indications:

• Previous episode of SBP
• Ascitic protein <1.5g/dL + CTP ≥9 or creatinine ≥1.2mg/dL
• Agent: Trimethoprim-sulfamethoxazole DS daily or ciprofloxacin 500mg daily

Hepatorenal Syndrome (HRS)

Hepatorenal syndrome represents acute kidney injury in the setting of advanced cirrhosis without other identifiable causes.

HRS-AKI Diagnostic Criteria:

✓ Cirrhosis with ascites ✓ AKI per ICA-AKI criteria ✓ No response to diuretic withdrawal + volume expansion ✓ Absence of shock, nephrotoxins, structural kidney disease

Treatment Approach:

1. Vasoconstrictor therapy: Terlipressin (preferred) or midodrine + octreotide
2. Albumin: 1g/kg daily (maximum 100g)
3. Duration: Continue until creatinine <1.5mg/dL or 14 days
4. Response rates: 40-50% with combination therapy

Long-term Outcomes

Survival by Complication:

[KEY_CONCEPT] Decompensation events are associated with exponential increases in mortality, emphasizing the importance of early transplant evaluation.

HCC Surveillance Outcomes

Surveillance Effectiveness:

• Early detection: 60-70% of HCC detected at early stage with surveillance
• No surveillance: <30% detected at early stage
• Survival benefit: 37% reduction in HCC-related mortality
• Cost-effectiveness: $30,000-50,000 per quality-adjusted life year

Treatment Response by Stage:

[CLINICAL_PEARL] Milan criteria (single lesion ≤5cm or 2-3 lesions ≤3cm each, no vascular invasion) define optimal transplant candidates with 5-year survival >70%.

Quality of Life Considerations

Factors Affecting Prognosis:

• Nutritional status: Malnutrition present in 50-90% of cirrhotic patients
• Frailty: Independent predictor of waitlist mortality
• Sarcopenia: Associated with increased complications post-transplant
• Social support: Critical for medication adherence and follow-up

Palliative Care Integration:

• Timing: Consider when MELD >20 or multiple hospitalizations
• Goals: Symptom management, advance directive discussions
• Outcomes: Improved quality of life, reduced healthcare utilization